Real-World outcomes in COPD patients starting Trixeo (budesonide/glycopyrronium/formoterol) in Spain.

Trial Identifier:	D5980R00096
Sponsor:	AstraZeneca
NCTID::	NCT06321731
Start Date:	June 2024
Primary Completion Date:	November 2024
Study Completion Date:	November 2024
Condition:	Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.